$0.13
(5.65%)
Add to watchlist
Create an alert
Stocks and Shares ISAConnect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Company Information
About this company
Key people
David L. Szekeres
President
Barry D. Quart
Chief Executive Officer and Director
Kimberly J. Manhard
Executive Vice President, Chief Development Officer
Lisa Peraza
Vice President - Finance
Raul Collazo
Vice President - Global Medical Affairs
Lei Sun
Vice President - Biologics and Head of CMC
Jeff Cohn
General Counsel and Corporate Secretary
Kleanthis G. Xanthopoulos
Non-Executive Independent Chairman of the Board
James A. Schoeneck
Director
James Z. Huang
Independent Director
Jean I. Liu
Independent Director
Karen J. Wilson
Independent Director
Click to see more
Key facts
- Shares in issue0.00
- EPICCNTB
- ISINKYG235491019
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$130.26m
- Employees62
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.